pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 8·1 min read
save

Endpoints News identifies 25 biopharma CEOs earning $25M or more in 2025

Jun 8, 2026·read at Endpoints ↗Neutral

Endpoints News released a ranking of the highest-paid chief executives in the biopharma sector for 2025.

For the first time in four years the publication raised the minimum compensation threshold from $20 million to $25 million, creating a list of 25 CEOs whose total pay surpassed that level.

The list underscores the concentration of executive compensation at the top of the industry and reflects broader trends in pay across biotech and pharmaceutical companies.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Biopharma's top-paid CEOs of 2025: 25 making $25M+”

read at Endpoints ↗
83 words · retrieved Jun 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints
  • 2h agoSuperluminal secures $60M for Phase 1 of genetic obesity drugEndpoints
  • 2h agoGSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontEndpoints
  • 10h agoUltragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsEndpoints
  • 17h agoFDA leaders project enhanced scrutiny of foreign dataEndpoints